Physician profile
Francesco Celi
NPI 1427320761
$48,164.89
in general payments reported to CMS, 2019-2025
10 companies · $12K in 2025
The $12K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,129 · 2020: $2,748 · 2021: $22K · 2022: $5,460 · 2023: $1,757 · 2024: $1,455 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,239 · Honoraria: $5,917 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,218 · Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,239.00 |
| Honoraria | $5,916.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,217.96 |
| Food and Beverage | $796.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $13,437.50 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $12,072.90 | 2024-2025 | Recorlev |
| Avion Pharmaceuticals | $10,775.29 | 2021-2023 | NP Thyroid 60 |
| Ibsa Pharma INC. | $4,656.15 | 2019-2023 | Tirosint, Tirosint, Licart |
| Acella Pharmaceuticals, LLC | $2,883.73 | 2020-2023 | NP Thyroid 60 |
| Horizon Therapeutics Plc | $1,800.00 | 2022 | |
| Novo Nordisk INC | $1,380.50 | 2020-2024 | |
| Ascendis Pharma Endocrinology INC | $1,131.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.82 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesco Celi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.